drugset
drugset / Trial / NCT02829723

A Study of BLZ945 Single Agent or BLZ945 in Combination With PDR001 in Advanced Solid Tumors

NCT02829723 ↗

Phase 1/2 Terminated 192 enrolled Novartis Pharmaceuticals
Non-randomizedParallel-groupOpen-labelTreatment

Summary

The purpose of this first-in-human (FIH) study of BLZ945 given as a single agent or in combination with PDR001 was to characterize the safety, tolerability, pharmacokinetics (PK), pharmacodynamics, and anti-tumor activity of BLZ945, administered orally, as a single agent or in combination with PDR001, administered intravenously (i.v.) in adult patients with advanced solid tumors.

Timeline

Start
2016-10-21
Primary completion
2022-12-01
Completion
2022-12-01

Drugs

EvaluationDrugModalityDoseRoute
Subject SOTULETINIB Small molecule — Oral
Subject Spartalizumab Monoclonal antibody 400 mg Intravenous

Indications

cancer